T
Takafumi Majima
Researcher at Kyoto University
Publications - 18
Citations - 556
Takafumi Majima is an academic researcher from Kyoto University. The author has contributed to research in topics: Osteoporosis & N-terminal telopeptide. The author has an hindex of 12, co-authored 18 publications receiving 526 citations. Previous affiliations of Takafumi Majima include Kyoto Medical Center.
Papers
More filters
Journal ArticleDOI
Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome
Noriko Satoh,Akira Shimatsu,Kazuhiko Kotani,Akihiro Himeno,Takafumi Majima,Kazunori Yamada,Takayoshi Suganami,Yoshihiro Ogawa +7 more
TL;DR: This study is the first demonstration that EPA improves arterial stiffness and is less influenced by BP, possibly through the suppression of SAA–LDL, thereby leading to a reduction in the frequency of cardiovascular disease development in metabolic syndrome.
Journal ArticleDOI
Decreased bone mineral density at the distal radius, but not at the lumbar spine or the femoral neck, in Japanese type 2 diabetic patients
Takafumi Majima,Yasato Komatsu,T. Yamada,Y. Koike,Michika Shigemoto,C. Takagi,I. Hatanaka,Kazuwa Nakao +7 more
TL;DR: In type 2 diabetic patients, negative correlation between BMD and the mean HbA1c during the previous 2 years was found significantly at the distal radius in both genders and at the femoral neck in women.
Journal ArticleDOI
Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia.
Takafumi Majima,Yasato Komatsu,Atsushi Fukao,Kiyoshi Ninomiya,Tadashi Matsumura,Kazuwa Nakao +5 more
TL;DR: The findings suggest that atorvastatin may have potentially beneficial effects on bone metabolism in patients with hypercholesterolemia mostly by reducing bone resorption rather than by stimulating bone formation.
Journal ArticleDOI
Urinary Cystatin C as a Potential Risk Marker for Cardiovascular Disease and Chronic Kidney Disease in Patients with Obesity and Metabolic Syndrome
Noriko Satoh-Asahara,Takayoshi Suganami,Takafumi Majima,Kazuhiko Kotani,Yasuhisa Kato,Rika Araki,Kazunori Koyama,Taiichiro Okajima,Makito Tanabe,Mariko Oishi,Akihiro Himeno,Shigeo Kono,Akira Sugawara,Masakazu Hattori,Yoshihiro Ogawa,Akira Shimatsu +15 more
TL;DR: It is demonstrated that UCCR is significantly associated with renal dysfunction, the severity of MS, arterial stiffness, and weight change in obese patients, and the data suggest that U-CysC could serve as a CVD and CKD risk factor in patients with obesity and MS.
Journal ArticleDOI
Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in japanese women with type 2 diabetes mellitus
Takafumi Majima,Yasato Komatsu,Kentaro Doi,Michika Shigemoto,Chieko Takagi,Atsushi Fukao,Jerry Corners,Kazuwa Nakao +7 more
TL;DR: The results demonstrate the safety and efficacy of low-dose pioglitazone, suggesting that it could be another good choice of treatment for Japanese women with T2DM.